Henny Azmanov
Clinical FellowAbout
Research
Publications
2026
A feasibility open-label clinical trial utilizing second-generation artificial intelligence based on the constrained-disorder principle in patients with Parkinson's disease
Lehmann H, Azmanov H, Hershkovitz Y, Hurvitz N, Agus S, Berg M, Arkadir D, Ilan Y. A feasibility open-label clinical trial utilizing second-generation artificial intelligence based on the constrained-disorder principle in patients with Parkinson's disease. IBRO Neuroscience Reports 2026, 20: 448-456. PMID: 41853628, PMCID: PMC12993379, DOI: 10.1016/j.ibneur.2026.02.019.Peer-Reviewed Original ResearchPatient Global ImpressionUnified Parkinson's Disease Rating ScaleOpen-labelClinical improvementPatient Global Impression of ImprovementClinical trialsGlobal Impression of ImprovementDouble-masked controlled trialAssociated with clinical improvementPGI-I scaleImpression of ImprovementSingle-center studyPD patientsOpen-label designLevodopa-induced dyskinesiaArtificial intelligenceFeasibility clinical trialDrug lossParkinson's diseaseWilcoxon signed-rank testResponse to levodopaSigned-rank testDosing regimensSubjective improvementTherapeutic regimensWhat is new in pleural infections?
Kenig A, Azmanov H, Alsharif N, Idais I, Kuint R, Darawshy F, Kuint R. What is new in pleural infections? Breathe 2026, 22: 250038. PMID: 41853055, PMCID: PMC12993744, DOI: 10.1183/20734735.0038-2025.Peer-Reviewed Original ResearchPleural infectionTreatment of pleural infectionShort course of antibioticsCourse of antibioticsPleural fluid biomarkersPersonalised approach to treatmentPoint-of-care ultrasoundApproach to treatmentMedical thoracoscopyPatient selectionRisk stratificationCausative pathogenInfection managementDiagnostic strategiesEnzyme therapyRisk factorsAntibiotic selectionNovel bloodPatient outcomesClinical settingInfectionMicrobiological techniquesDisease mechanismsPatientsFluid biomarkers
2025
Forced Oscillatory Technique for Identifying and Quantifying Pulmonary Involvement in Patients with Sarcoidosis
Kuint R, Grauer Y, Darawshy F, Padawer D, Azmanov H, Kenig A, Abutbul A, Berkman N. Forced Oscillatory Technique for Identifying and Quantifying Pulmonary Involvement in Patients with Sarcoidosis. 2025, pa5127. DOI: 10.1183/13993003.congress-2025.pa5127.Peer-Reviewed Original ResearchFire: argon plasma coagulation, diathermy and laser
Azmanov H, Darawshy F. Fire: argon plasma coagulation, diathermy and laser. Breathe 2025, 21: 240246. PMID: 40673066, PMCID: PMC12260910, DOI: 10.1183/20734735.0246-2024.Peer-Reviewed Original ResearchArgon plasma coagulationCentral airway obstructionPlasma coagulationAirway obstructionMinimally invasive techniquesRisk of complicationsTumor debulkingAblation therapyLaser therapyMalignant conditionsMechanical debulkingInterventional pulmonologyBronchoscopy techniquesEffective haemostasisInvasive techniquesAirway pathologySuperficial lesionsPatient factorsLesion locationPatient outcomesDiathermyProcedural nuancesDebulkingHigh-frequency electric currentTissue contactNon-classical pulmonary exacerbation in cystic fibrosis revealing ALK-Translocated lung cancer: A case report
Hadhud M, Arnon J, Hershko-Moshe A, Hollander A, Hurvitz-Lehmann N, Potruch A, Azmanov H, Kuint R, Hiller N, Picard E, Sebbag-Sznajder N, Leebhoff S, Wilschanski M, Grunewald M, Birimberg-Schwartz L, Cohen-Cymberknoh M. Non-classical pulmonary exacerbation in cystic fibrosis revealing ALK-Translocated lung cancer: A case report. Respiratory Medicine Case Reports 2025, 53: 102171. PMID: 39980610, PMCID: PMC11841201, DOI: 10.1016/j.rmcr.2025.102171.Peer-Reviewed Original ResearchTyrosine kinase inhibitorsALK-translocated lung cancerNon-small cell lung carcinomaLung cancerPulmonary exacerbationsAtypical presentationCystic fibrosisTyrosine kinase inhibitor therapyDegree of clinical suspicionALK inhibitor therapyALK inhibitor treatmentElevated liver enzymesCell lung carcinomaSevere respiratory distressALK-EML4Patient-derived intestinal organoidsCFTR modulatorsCFTR activityTumor regressionInhibitor therapyClinical suspicionCF patientsLung massCF diseaseClinical improvement
2024
P021 Non-classical pulmonary exacerbation in a patient with cystic fibrosis: case report
Hadhud M, Arnon J, Hershko-Moshe A, Hollander A, Hurvitz-Lehmann N, Potruch A, Vainer G, Azmanov H, Kuint R, Picard E, Cohen-Cymberknoh M. P021 Non-classical pulmonary exacerbation in a patient with cystic fibrosis: case report. Journal Of Cystic Fibrosis 2024, 23: s73. DOI: 10.1016/s1569-1993(24)00329-1.Peer-Reviewed Original ResearchPrevalence and Clinical Implications of Nontuberculous Mycobacteria Isolation and Infection among Patients with Bronchiectasis in the Jerusalem Area.
Kuint R, Azmanov H, Shalom A, Berkman N. Prevalence and Clinical Implications of Nontuberculous Mycobacteria Isolation and Infection among Patients with Bronchiectasis in the Jerusalem Area. Israel Medical Association Journal 2024, 26: 180-185. PMID: 38493330.Peer-Reviewed Original ResearchConceptsPrevalence of nontuberculous mycobacteriaNontuberculous mycobacteriaComputerized medical chartsBronchiectasis patientsRetrospective observational research studyMedical charts of patientsIsolates of Pseudomonas aeruginosaNontuberculous mycobacteria isolationNTM colonizationNTM patientsNTM pulmonary diseaseCharts of patientsNTM diseaseChronic lung diseaseHadassah Medical CenterClinical implicationsPulmonary function testsYears of agePrognostic significanceGroup of controlsBronchiectasisChronic inflammationClinical differencesLung diseaseMicrobiological data
2023
Low-Dose Colchicine Attenuates Sepsis-Induced Liver Injury: A Novel Method for Alleviating Systemic Inflammation
Kenig A, Keidar-Haran T, Azmanov H, Kessler A, Kolben Y, Tayri-Wilk T, Kalisman N, Weksler-Zangen S, Ilan Y. Low-Dose Colchicine Attenuates Sepsis-Induced Liver Injury: A Novel Method for Alleviating Systemic Inflammation. Inflammation 2023, 46: 963-974. PMID: 36656466, DOI: 10.1007/s10753-023-01783-9.Peer-Reviewed Original ResearchConceptsLow-dose colchicineGut immune systemLiver injuryLPS-induced sepsisImmune systemCytokine levelsSystemic inflammationBiochemical markersLiver pathologyEnd-organ injuryPro-inflammatory cytokine levelsMurine sepsis scoreMultiple inflammatory disordersSepsis-induced liver injuryLiver enzyme levelsAlpha 1-antitrypsinCreatinine levelsLow-doseBlood countSepsis scoreCytokines TNFaSeptic miceInflammatory disordersSepsisPublic health challengeUsing chronobiology-based second-generation artificial intelligence digital system for overcoming antimicrobial drug resistance in chronic infections
Kolben Y, Azmanov H, Gelman R, Dror D, Ilan Y. Using chronobiology-based second-generation artificial intelligence digital system for overcoming antimicrobial drug resistance in chronic infections. Annals Of Medicine 2023, 55: 311-318. PMID: 36594558, PMCID: PMC9815249, DOI: 10.1080/07853890.2022.2163053.Peer-Reviewed Original ResearchConceptsChronic infectionAntimicrobial agentsAntimicrobial resistancePatient adherenceLong-term effectsAntimicrobial drug resistanceDrug administration timeHost response to infectionEffects of antimicrobial agentsArtificial intelligence (AI)-based technologiesProblem of antimicrobial resistanceResponse to infectionImplementation of variabilityDrug resistanceSustained responseClinical trialsIntelligent digital systemsAI technologyResistance mechanismsInfectionAdministration timeResistance developmentSecond-generation systemAntimicrobial stewardsDigital systemsColchicine at a Low Dose Reduces Liver Inflammation in a Model of Immune-Mediated Hepatitis
Azmanov H, Keidar-Haran T, Kenig A, Kessler A, Kolben Y, Weksler- Zangen S, Ilan Y. Colchicine at a Low Dose Reduces Liver Inflammation in a Model of Immune-Mediated Hepatitis. Archives Of Clinical And Biomedical Research 2023, 07 DOI: 10.26502/acbr.50170334.Peer-Reviewed Original Research